8.45k followers • 10 symbols Watchlist by Yahoo Finance
This basket consists of stocks gaining popularity from health and wellness.
Curated by Yahoo Finance
While America is notorious for its soaring obesity rates, Gallup found last year that people in the US have been exercising more frequently in the past few years. The companies on this list track fitness goals, provide workout gear and supply nutritious food for Americans craving a healthy lifestyle.How did we choose these stocks?
Each of these stocks was chosen by the Yahoo Finance editorial staff.Who made these selections?
Yahoo Finance is the most-read business website in the US, garnering roughly 75 million unique visitors every month. The site has extensive coverage of the markets, travel, technology and general business.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|NKE||NIKE, Inc.||116.07||+1.97||+1.73%||16:00 GMT-4||4.41M||7.19M||182.06B|
|LULU||Lululemon Athletica Inc.||321.69||+4.71||+1.49%||16:00 GMT-4||754.95k||1.34M||41.06B|
|DXCM||DexCom, Inc.||89.83||+1.59||+1.80%||16:00 GMT-4||1.91M||3.50M||35.00B|
|DKS||Dick's Sporting Goods, Inc.||107.24||+2.13||+2.03%||16:00 GMT-4||803.49k||2.58M||8.64B|
|UA||Under Armour, Inc.||9.05||+0.16||+1.80%||16:04 GMT-4||1.98M||5.52M||4.34B|
|FL||Foot Locker, Inc.||31.52||+0.68||+2.20%||16:00 GMT-4||1.45M||2.69M||2.98B|
|HLF||Herbalife Nutrition Ltd.||29.13||+0.28||+0.97%||16:00 GMT-4||728.34k||1.35M||2.85B|
|MED||Medifast, Inc.||136.79||+4.77||+3.61%||16:00 GMT-4||259.12k||165.29k||1.51B|
Investors who take an interest in Medifast, Inc. ( NYSE:MED ) should definitely note that the Lead Independent...
The first reason to buy DexCom stock is that it's slumping as a result of short-term issues that won't have much of an impact once they're resolved. Its latest continuous glucose monitor (CGM) in development for diabetes management, the G7, hit a snag in its approval process with regulators at the Food and Drug Administration (FDA). Then, when the G7 ultimately launches in the U.S., DexCom's revenue growth will likely pick up once more, and its stock price should follow.
Nvidia (NASDAQ: NVDA) warns that second-quarter revenue will be lower than previous estimates. Why Nvidia's long-term thesis appears to be intact. Does the former highflier have enough of a moat to fend off the likes of Amazon (NASDAQ: AMZN)?